Design Therapeutics reports early Friedreich's ataxia trial shows 6.4-point improvement; Vincentage reports Chinese obesity data

Design Therapeutics disclosed Phase 1/2 results for its Friedreich's ataxia candidate DT-216P2. The trial administered a 1 mg/kg dose and reported an average 6.4-point improvement on the study endpoint.

The data represent early evidence of clinical benefit in a disease with limited treatment options. The company highlighted the magnitude of change as encouraging for further development.

Separately, Chinese partner Vincentage shared obesity study outcomes, indicating progress in that program. The briefing also referenced recent updates on AstraZeneca’s Enhertu and Tecentriq, though details were not provided.